Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 9712831, 7 pages
http://dx.doi.org/10.1155/2016/9712831
Research Article

Gastrointestinal Symptoms of Patients with Fabry Disease

1Department of Pediatrics, “Magna Graecia” University, Viale Pio X, 88100 Catanzaro, Italy
2Translational Medical Sciences, Section of Pediatrics, “Federico II” University, Naples, Italy

Received 16 June 2015; Revised 10 September 2015; Accepted 13 September 2015

Academic Editor: Paul Enck

Copyright © 2016 Licia Pensabene et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Mehta, R. Ricci, U. Widmer et al., “Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey,” European Journal of Clinical Investigation, vol. 34, no. 3, pp. 236–242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Spada, S. Pagliardini, M. Yasuda et al., “High incidence of later-onset Fabry disease revealed by newborn screening,” American Journal of Human Genetics, vol. 79, no. 1, pp. 31–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. W. R. Wilcox, J. P. Oliveira, R. J. Hopkin et al., “Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry,” Molecular Genetics and Metabolism, vol. 93, no. 2, pp. 112–128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. C. Vedder, A. Strijland, M. A. vd Bergh Weerman, S. Florquin, J. M. F. G. Aerts, and C. E. M. Hollak, “Manifestations of Fabry disease in placental tissue,” Journal of Inherited Metabolic Disease, vol. 29, no. 1, pp. 106–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Pintos-Morell and M. Beck, “Fabry disease in children and the effects of enzyme replacement treatment,” European Journal of Pediatrics, vol. 168, no. 11, pp. 1355–1363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Sestito, F. Ceravolo, and D. Concolino, “Anderson-fabry disease in children,” Current Pharmaceutical Design, vol. 19, no. 33, pp. 6037–6045, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. W. H. Kang, S. I. Chun, and S. Lee, “Generalized anhidrosis associated with Fabry's disease,” Journal of the American Academy of Dermatology, vol. 17, no. 5, part 2, pp. 883–887, 1987. View at Publisher · View at Google Scholar · View at Scopus
  8. M. G. Bouwman, S. M. Rombach, E. Schenk et al., “Prevalence of symptoms in female Fabry disease patients: a case-control survey,” Journal of Inherited Metabolic Disease, vol. 35, no. 5, pp. 891–898, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Schiffmann, D. G. Warnock, M. Banikazemi et al., “Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy,” Nephrology Dialysis Transplantation, vol. 24, no. 7, pp. 2102–2111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. K. D. MacDermot, A. Holmes, and A. H. Miners, “Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females,” Journal of Medical Genetics, vol. 38, no. 11, pp. 769–775, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Mehta, M. Beck, F. Eyskens et al., “Fabry disease: a review of current management strategies,” QJM, vol. 103, no. 9, pp. 641–659, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Rigoldi, D. Concolino, A. Morrone et al., “Intrafamilial phenotypic variability in four families with anderson-fabry disease,” Clinical Genetics, vol. 86, no. 3, pp. 258–263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Ramaswami, “Update on role of agalsidase alfa in management of Fabry disease,” Drug Design, Development and Therapy, no. 5, pp. 155–173, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. D. P. Germain, S. Waldek, M. Banikazemi et al., “Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with fabry disease,” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1547–1557, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Pisani, B. Visciano, G. D. Roux et al., “Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature,” Molecular Genetics and Metabolism, vol. 107, no. 3, pp. 267–275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Hoffmann, M. Beck, G. Sunder-Plassmann, W. Borsini, R. Ricci, and A. Mehta, “Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy—a retrospective analysis from the Fabry Outcome Survey,” Clinical Journal of Pain, vol. 23, no. 6, pp. 535–542, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Parini, M. Rigoldi, F. Santus et al., “Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index,” Clinical Genetics, vol. 74, no. 3, pp. 260–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Whybra, C. Kampmann, I. Willers et al., “Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes,” Journal of Inherited Metabolic Disease, vol. 24, no. 7, pp. 715–724, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Hoffmann, D. Reinhardt, and B. Koletzko, “Effect of enzyme-replacement therapy on gastrointestinal symptoms in fabry disease,” European Journal of Gastroenterology and Hepatology, vol. 16, no. 10, pp. 1067–1069, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Dehout, D. Roland, S. T. de Granseigne, B. Guillaume, and L. Van Maldergem, “Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease,” Journal of Inherited Metabolic Disease, vol. 27, no. 4, pp. 499–505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ries, U. Ramaswami, R. Parini et al., “The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents,” European Journal of Pediatrics, vol. 162, no. 11, pp. 767–772, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. K. D. MacDermot, A. Holmes, and A. H. Miners, “Natural history of Fabry disease in affected males and obligate carrier females,” Journal of Inherited Metabolic Disease, vol. 24, no. 2, pp. 13–14, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Banikazemi, T. Ullman, and R. J. Desnick, “Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy,” Molecular Genetics and Metabolism, vol. 85, no. 4, pp. 255–259, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Buda, A. Wieteska-Klimczak, J. Ksiazyk et al., “Diagnostic problems in a 17-year-old patient with gastrointestinal manifestations of Fabry disease,” Medycyna Wieku Rozwojowego, vol. 15, no. 1, pp. 69–72, 2011. View at Google Scholar · View at Scopus
  25. F. Cremonini and N. J. Talley, “Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors,” Gastroenterology Clinics of North America, vol. 34, no. 2, pp. 189–204, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Boccia, F. Manguso, P. Coccorullo, P. Masi, L. Pensabene, and A. Staiano, “Functional defecation disorders in children: PACCT criteria versus Rome II criteria,” Journal of Pediatrics, vol. 151, no. 4, pp. 394.e1–398.e1, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. D. A. Drossman, E. Corazzini, M. Delvaux, R. C. Spiller, N. J. Talley, and W. E. Thompson, Degnon Associates, Rome III. The Functional Gastrointestinal Disorders, 3rd edition, 2006, http://www.romecriteria.org/assets/pdf/JClinGastro.pdf.
  28. L. S. Walker, A. Caplan, and A. Rasquin-Weber, Manual for the Questionnaire on Pediatric Gastrointestinal Symptom, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn, USA, 2000.
  29. L. S. Walker, T. A. Lipani, J. W. Greene et al., “Recurrent abdominal pain: symptom subtypes based on the Rome II Criteria for pediatric functional gastrointestinal disorders,” Journal of Pediatric Gastroenterology and Nutrition, vol. 38, no. 2, pp. 187–191, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Caplan, L. Walker, and A. Rasquin, “Development and preliminary validation of the questionnaire on pediatric gastrointestinal symptoms to assess functional gastrointestinal disorders in children and adolescents,” Journal of Pediatric Gastroenterology and Nutrition, vol. 41, no. 3, pp. 296–304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Caplan, L. Walker, and A. Rasquin, “Validation of the pediatric Rome II criteria for functional gastrointestinal disorders using the questionnaire on pediatric gastrointestinal symptoms,” Journal of Pediatric Gastroenterology and Nutrition, vol. 41, no. 3, pp. 305–316, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. K. D. MacDermot, A. Holmes, and A. H. Miners, “Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males,” Journal of Medical Genetics, vol. 38, no. 11, pp. 750–760, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. C. I. A. Jack, A. I. Morris, D. G. Nasmyth, and N. Carroll, “Colonic involvement in Fabry's disease,” Postgraduate Medical Journal, vol. 67, no. 788, pp. 584–585, 1991. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Dütsch, H. Marthol, B. Stemper, M. Brys, T. Haendl, and M. J. Hilz, “Small fiber dysfunction predominates in fabry neuropathy,” Journal of Clinical Neurophysiology, vol. 19, no. 6, pp. 575–586, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. A. H. Miners, A. Holmes, L. Sherr, C. Jenkinson, and K. D. MacDermot, “Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention,” Quality of Life Research, vol. 11, no. 2, pp. 127–133, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Hoffmann, M. Schwarz, A. Mehta, and S. Keshav, “Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy,” Clinical Gastroenterology and Hepatology, vol. 5, no. 12, pp. 1447–1453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. A. P. S. Hungin, L. Chang, G. R. Locke, E. H. Dennis, and V. Barghout, “Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact,” Alimentary Pharmacology & Therapeutics, vol. 21, no. 11, pp. 1365–1375, 2005. View at Publisher · View at Google Scholar · View at Scopus